drugset / Trial / NCT06474442
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.
Timeline
- Start
- 2025-04-28
- Primary completion
- 2026-12
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BD111 | CRISPR / gene editing | 1e+07 unknown | Other |
| Background | Ganciclovir | Small molecule | — | Topical |
| Background | Prednisolone | Other / unclassified | — | Topical |
| Background | Valacilovir | Unknown | — | Oral |